Adult Neuronal Ceroid Lipofuscinosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Adult Neuronal Ceroid Lipofuscinosis

Adult Neuronal Ceroid Lipofuscinosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

A genetically heterogeneous group of neuronal ceroid lipofuscinoses (NCLs) with onset during the third decade of life, characterized by dementia, seizures and loss of motor capacities, and sometimes associated with visual loss caused by retinal degeneration. Also known as adult NCL, ANCL, Kufs syndrome, Kufs disease, Parry disease, neuronal ceroid lipofuscinosis, adult type. Mutations in several different genes can cause adult neuronal ceroid lipofuscinosis. These include the CLN6 gene for type A and the CTSF gene for type B. There are also people with adult onset of neuronal ceroid lipofuscinosis due to changes in the PPT1 gene, the CLN5 gene, CTSD gene, and the GRN gene. Adult onset disease that affects vision or the heart has been found to be caused by changes in the CLN3 gene, and the MFSD8 gene. Some very specific changes in the DNAJC5 gene can also cause adult onset neuronal ceroid lipofuscinoses.

Classification-
Type A presents initially with generalized tonic–clonic seizures, followed by progressive myoclonic seizures, photosensitivity, dementia, ataxia, and pyramidal and extrapyramidal signs.

Type B starts with behavioral disturbances and dementia, and, subsequently, motor disturbances, particularly tic-like facial dyskinesia; ataxia, extrapyramidal, and bulbar signs are added.

Epidemiology- the prevalence is estimated to be about 1.5 people per 9,000,000 in the general population.

Competitive landscape of Adult Neuronal Ceroid Lipofuscinosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Adult Neuronal Ceroid Lipofuscinosis across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Adult Neuronal Ceroid Lipofuscinosis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Adult Neuronal Ceroid Lipofuscinosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset   Company         Stage
1          GB226 Genor   Biopharma Co., Ltd. Phase 2
2          AL3818             Advenchen Laboratories, LLC Phase 3
3          Axitinib and Pembrolizumab       Merck Sharp & Dohme Corp. Phase 2
4          Perifosine         AEterna Zentaris Phase 2
5          FAZ053            Novartis Pharmaceuticals Phase 1

Alveolar soft part sarcoma (ASPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Alveolar soft part sarcoma (ASPS)

Alveolar soft part sarcoma (ASPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Alveolar soft part sarcoma (ASPS) is a malignant soft tissue tumor, which is a tumor that starts in the soft connective tissues of the body such as fat, muscles, or nerves. The two genes involved in ASPS are the alveolar soft part sarcoma critical region 1 (ASPSCR1) gene on chromosome 17 and TFE3 gene on chromosome X. In ASPS, the TFE3 gene breaks off from the X chromosome and attaches onto the ASPSCR1 gene on chromosome 17. This unbalanced translocation creates a new so-called “fusion” gene known as ASPSCR1-TFE3.

Epidemiology-

ASPS is one of the rarest sarcomas. Soft tissue sarcomas make up 1% of all cancers and ASPS makes up only 0.2% to 1% of all soft tissue sarcomas. There are about 80 cases diagnosed per year in the United States.

Competitive landscape of Alveolar soft part sarcoma (ASPS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Alveolar soft part sarcoma (ASPS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Alveolar soft part sarcoma (ASPS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Alveolar soft part sarcoma (ASPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company         Stage
1          GB226 Genor    Biopharma Co., Ltd. Phase 2
2.         AL3818 Advenchen Laboratories, LLC Phase 3
3          Axitinib and Pembrolizumab       Merck Sharp & Dohme Corp. Phase 2
4          Perifosine         AEterna Zentaris Phase 2
5          FAZ053            Novartis Pharmaceuticals Phase 1

Congenital atransferrinemia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Congenital atransferrinemia

Congenital atransferrinemia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Congenital atransferrinemia is a very rare hematologic disease caused by a transferrin (TF) deficiency and characterized by microcytic, hypochromic anemia (manifesting with pallor, fatigue and growth retardation) and iron overload, and that can be fatal if left untreated. Transferrinemia / hypotransferrinemia is principally caused by mutations of the transferrin (TF) gene. the transferrin (TF) gene is located at band 21 on the long arm (q) of chromosome 3 (3q21).

Competitive landscape of Congenital atransferrinemia includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Congenital atransferrinemia across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Congenital atransferrinemia Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Congenital atransferrinemia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Chemotherapy-induced peripheral neuropathy (CIPN) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Chemotherapy-induced peripheral neuropathy (CIPN)

Chemotherapy-induced peripheral neuropathy (CIPN) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Adverse effects induced by cancer treatment, 20-100% of patients develop a condition known as chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when peripheral nerves are damaged, resulting in abnormal sensory function, and pain or loss of motor control. This condition sometimes leads to chemotherapy dose decrease or cessation, thereby limiting the efficacy of cancer treatment. The review here discusses the latest aspects of chemotherapy-associated peripheral neuropathy.

Epidemiology-

According to Thelansis, the estimated total patient pool of chemotherapy-induced peripheral neuropathy (CIPN) in 8 MM countries is reported to be 3.35 MN in 2020, 3.47 MN in 2025, and 3.57 MN by 2030. Overall growth of the patient pool for CIPN in 8MM countries is majorly due to patient available to each treatment modalities and newly diagnosed patient pool.

Competitive landscape of Chemotherapy-induced peripheral neuropathy (CIPN) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Chemotherapy-induced peripheral neuropathy (CIPN) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Chemotherapy-induced peripheral neuropathy (CIPN) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Chemotherapy-induced peripheral neuropathy (CIPN) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 Calmangafodipir Egetis Therapeutics / PledPharma AB Phase 3
2 TRK-750 Toray Industries, Inc Phase 2
3 Olesoxime (TRO19622) Hoffmann-La Roche Phase 2
4 Calmangafodipir PledPharma AB Phase 1
5 leteprinim potassium (Neotrofin) NeoTherapeutics Phase 2
6 thrombomodulin alfa Asahi Kasei Pharma America Corporation Phase 2

Abdominal Aortic Aneurysm (AAA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Abdominal Aortic Aneurysm (AAA)

Abdominal Aortic Aneurysm (AAA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

An abdominal aortic aneurysm (AAA) is an enlarged area in the lower part of the major vessel that supplies blood to the body (aorta). The aorta runs from your heart through the center of the chest and abdomen. The prognosis of the disease is poor, following the rupture of an abdominal aortic aneurysm, the risk of death is approximately 80%. Most patients die before reaching the hospital. In most patients, the outcome is poor and surgical repair is only successful in 50% of cases with a ruptured aneurysm.

Epidemiology-

The annual incidence of new AAA diagnoses is approximately 0.4 to 0.67 percent in Western populations. This equates to 2.5 to 6.5 aneurysms per 1000 person-years. Age significantly impacts the incidence. As an example, in one study, among men aged 65 to 74 years, the incidence was 55 per 100,000 person-years, increasing to 112 per 100,000 person-years for men aged 75 to 85 years, this further increased to 298 per 100,000 person-years for those older than 85.

The market is expected to show a very strong growth throughout the study period (2020 - 2030), growing at a CAGR of ~7.6%. Major drivers of the growth are the newer pharmacotherapies which are expected to launch the market in the near future.

Competitive landscape of Abdominal Aortic Aneurysm (AAA) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Abdominal Aortic Aneurysm (AAA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Abdominal Aortic Aneurysm (AAA) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Abdominal Aortic Aneurysm (AAA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No                Asset                Company                      Stage
1                      Alirocumab Regeneron Pharmaceuticals Phase 3
2          Metformin Glucophage 500mg (IR) tablets M90 Merck Serono GmbH, Germany Phase 3
3          Ticagrelor AstraZeneca Phase 2 1

Triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Triple-negative breast cancer (TNBC)

Triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Triple-negative breast cancers (TNBC) are a breast cancer subtype that lacks expression of both estrogen (ER) and progesterone (PR) hormone receptors, as well as human epidermal growth factor receptor 2 (HER2).

Epidemiology-

TNBC comprises 10% of all female breast cancer cases by subtype, which also includes HR+/HER2- disease (68%), HR+/HER2+ disease (10%), HR-/HER2+ disease (4%), and unknown subtype (8%).

As compared to the most common breast cancer subtype HR+/HER2- which is associated with 87 new cases per 100,000 women, the triple-negative subtype accounts for just 13 new cases per 100,000. 5-year relative survival rates can be impacted by subtype and staging.

Despite a total 5-year relative survival rate for all female breast cancers combined of 90%, the relative survival rate for TNBC is the worst at 76.7%.
The stage at diagnosis may be the most powerful factor in determining survival outcome, as shown by relative survival rates for TNBC of 91.2% if the disease is localized, but drops to 11.5% if the disease is distant.

Competitive landscape of Triple-negative breast cancer (TNBC) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Triple-negative breast cancer (TNBC) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Triple-negative breast cancer (TNBC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 Talimogene Laherparepvec Amgen Phase 1
2 leronlimab CytoDyn, Inc. Phase 2
3 Tumor infiltrating lymphocytes (TIL) LN-145 Iovance Biotherapeutics, Inc. Phase 2
4 LY3023414 and Prexasertib Eli Lilly and Company Phase 2
5 pembrolizumab Merck Sharp & Dohme Corp. Phase 3
6 PMD-026 Phoenix Molecular Designs Phase 1
7 CDX-011 Celldex Therapeutics Phase 2
8 PVX-410 OncoPep, Inc. Phase 2
9 Tak-228 & Tak-117 Takeda Phase 2
10 HX008+Cisplatin+Gemcitabine Taizhou Hanzhong biomedical co. LTD Phase 2
11 AZD2281 AstraZeneca Phase 1
12 Trilaciclib G1 Therapeutics, Inc. Phase 3
13 Magrolimab Gilead Sciences Phase 2
14 Sacituzumab Govitecan Everest Medicines Phase 2
15 TTAC-0001 and pembrolizumab combination PharmAbcine Phase 1
16 Atezolizumab and Nab-Paclitaxel Hoffmann-La Roche Phase 3
17 PQR309 and Eribulin PIQUR Therapeutics AG Phase 2
18 SAR566658 (ACT14884) Sanofi Phase 2
19 NK012 Nippon Kayaku Co., Ltd. Phase 2
20 ENMD-2076 CASI Pharmaceuticals, Inc. Phase 2
21 Apatinib Jiangsu HengRui Medicine Co., Ltd. Phase 2
22 EndoTAG-1 SynCore Biotechnology Co., Ltd. Phase 3
23 KN046 Jiangsu Alphamab Biopharmaceuticals Co., Ltd Phase 2
24 BLEX 404 Oral Liquid BioLite, Inc. Phase 2
25 OTS167PO OncoTherapy Science, Inc. Phase 1
26 Temsirolimus Plus Neratinib Puma Biotechnology, Inc. Phase 2
27 eryaspase ERYtech Pharma Phase 3
28 Niraparib combined with MGD013 Zai Lab (Shanghai) Co., Ltd. Phase 1

 

Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Fibromyalgia

Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Fibromyalgia is a syndrome characterized by chronic widespread pain at multiple tender points, joint stiffness, and systemic symptoms (e.g., mood disorders, fatigue, cognitive dysfunction, and insomnia) [1–4] without a well-defined underlying organic disease.

Fibromyalgia classification based on the triggers:

Cervical pathology.
Metabolic/endocrine conditions.
Inflammatory/autoimmune conditions.
Peripheral/central nervous system conditions.
Mixed

Epidemiology-

According to systematic literature survey and Thelansis disease modeling data Fibromyalgia disorder affects an estimated 10 million people in the U.S. and an estimated 3-6% of the world population. While it is most prevalent in women. 75-90 percent of the people who have FM are women.

Competitive landscape of Fibromyalgia includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Fibromyalgia across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Fibromyalgia Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 NYX-2925 Aptinyx Phase 2
2 ASP0819 Astellas Pharma Inc Phase 2
3 TD-9855 Group 1 Theravance Biopharma Phase 2
4 TNX-102 SL Tonix Pharmaceuticals, Inc. Phase 3
5 INC-1 Virios Therapeutics, Inc. Phase 2
6 Duloxetine Eli Lilly and Company Phase 3
7 [S,S]-Reboxetine Pfizer Phase 3
8 Fremanezumab - Dose A Teva Branded Pharmaceutical Phase 2
9 Device: AVACEN Thermal Exchange System Avacen, Inc. Phase 2
10 DS-5565 Syneos Health Phase 3
11 DS-5565 Daiichi Sankyo, Inc. Phase 3
12 Pregabalin Release Tablets Jiangsu HengRui Medicine Co., Ltd. Phase 3
13 GRT9906 Grünenthal GmbH Phase 2
14 ropinirole GlaxoSmithKline Phase 2
15 Lacosamide UCB Pharma Phase 2
16 KL16-012 Knop Laboratorios Phase 2
17 Injectafer American Regent, Inc. Phase 2
18 Botulinum toxin type A Ipsen Phase 2
19 Botulinum toxin type A Allergan Phase 3
20 Ibuprofen Spherium Biomed Phase 2
21 Erenumab-aooe (EREN) Novartis Pharmaceuticals Phase 2

Primary vitreoretinal lymphoma (PVRL) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Primary vitreoretinal lymphoma (PVRL)

Primary vitreoretinal lymphoma (PVRL) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Primary vitreoretinal lymphoma (PVRL) is a rare B-cell intraocular malignancy, commonly considered as a subset of primary central nervous system (CNS) lymphoma. Brain dissemination occurs in 60–90% of patients and it is the cause of the high mortality and morbidity of the disease. PVRL involves the vitreous, the retina, and the retinal pigment epithelium (RPE). According to literature around 15–20% of patients with primary central nervous system lymphoma (PCNSL) will develop PVRL later. The majority of PVRL is of B-cell origin. However, T-cell lymphomas and T-cell rich lymphomas can also develop within the eye.

Epidemiology-

PVRL, a rare intraocular malignancy, is a subset of PCNSL It is a rare disease, according to literature PVRL has an approximate incidence in ~20% patients with PCNSL and 0.03 to 0.1 cases per 100,000 people per year in the US. PVRL usually affects the adults in the fifth–sixth decades of life.

Competitive landscape of Primary vitreoretinal lymphoma (PVRL) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Primary vitreoretinal lymphoma (PVRL) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Primary vitreoretinal lymphoma (PVRL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Primary vitreoretinal lymphoma (PVRL) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 ADX-2191 Aldeyra Therapeutics, Inc. Phase 3

Alzheimer’s disease (AD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Alzheimer’s disease (AD)

Alzheimer’s disease (AD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Alzheimer's disease (AD) is a complex and heterogeneous neurodegenerative disorder, classified as either early onset (under 65 years of age), or late onset (over 65 years of age). Three main genes are involved in early onset AD: amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2). The apolipoprotein E (APOE) E4 allele has been found to be a main risk factor for late-onset Alzheimer's disease.

Epidemiology-

According to literature,in the US more than 6.2 million of all ages have Alzheimer's. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia in 2021. Seventy-two percent are 75 or older. One in nine people age 65 and older (11.3%) has Alzheimer's dementia.

Competitive landscape of Alzheimer’s disease (AD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Alzheimer’s disease (AD) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Alzheimer’s disease (AD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Alzheimer’s disease (AD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                     Stage
1          Albumin           Grifols Biologicals, LLC Phase 3
2          ANAVEX2-73    Anavex Life Sciences Corp. Phase 3
3          AL002              Alector Inc. Phase 2
4          ACC-001          Pfizer Phase 2
5          Lecanemab      Biogen Phase 3
6          Idalopirdine     H. Lundbeck A/S Phase 3
7          AD-35 60mg group       Medpace, Inc. Phase 2
8          ORM-12741      Orion Corporation, Orion Pharma Phase 2
9          ASN51             Asceneuron Pty Ltd. Phase 1
10        ELND005          Elan Pharmaceuticals Phase 2

Familial Amyloid Polyneuropathy (FAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Familial Amyloid Polyneuropathy (FAP)

Familial amyloid polyneuropathy (FAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid polyneuropathy is a progressive sensorimotor and autonomic neuropathy of adulthood onset. FAP is transmitted as an autosomal dominant trait and is caused by mutations in the TTR gene (18q12.1). The most common variant is the TTR Val30Met substitution for which several endemic foci have been identified most notably from Portugal, Japan and Sweden.

Epidemiology- According to literature review and Thelansis estimation, It occurs in approximately one in 5,000 to 10,000 individuals in the United States and accounts for about 0.5% of all cases of colorectal cancer. According to national registries, familial adenomatous polyposis occurs in 2.29-3.2 per 100,000 individuals.

Competitive landscape of Familial Amyloid Polyneuropathy (FAP) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Familial Amyloid Polyneuropathy (FAP) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Familial Amyloid Polyneuropathy (FAP) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Familial Amyloid Polyneuropathy (FAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Partner        Phase

1        Celebrex        Pfizer Inc.        Astellas       

Withdrawn from Market

2        ALFA        S.L.A. Pharma AG        N/A        III

3        CPP-1X/Sulindac        Mallinckrodt plc        Zeria; Cancer Prevention        III

4        Tremfya        Johnson & Johnson        MorphoSys; Otsuka        I

5        CPP-1X        Cancer Prevention Pharmaceuticals, Inc.        N/A        Preclinical
 

Methylmalonic Acidemia (MMA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Methylmalonic Acidemia (MMA)

Methylmalonic Acidemia (MMA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Methylmalonic acidemia/isolated methylmalonic acidemia/methylmalonic aciduria/MMA refers to a group of inherited conditions in which the body can’t breakdown certain parts of proteins and fats. This leads to a build-up of toxic substances and bouts of serious illness called decompensation events or metabolic crises. Isolated methylmalonic acidemia is caused by changes in one of five genes: MMUT, MMAA, MMAB, MMADHC, or MCEE. Methylmalonic acidemia with homocystinuria is caused by mutations in the MMADHC, LMBRD1 and ABCD4 genes. Other forms of methylmalonic acidemia are caused by changes in different genes.

Epidemiology- According to literature review and Thelansis estimation, about 1/80,000-1/100,000 babies are born with methylmalonic acidemia worldwide. In the United States, one study estimated that about 1/90,000 babies are born with methylmalonic acidemia.

Competitive landscape of Methylmalonic Acidemia (MMA) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Methylmalonic Acidemia (MMA) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Methylmalonic Acidemia (MMA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Methylmalonic Acidemia (MMA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Companies        Asset        Status

1        Recordati        Carglumic acid        Marketed in EU

2        ModernaTX, Inc.        mRNA 3704        Phase I/II

3        HemoShear Therapeutics        HST-103        In pre-clinical

4        HemoShear Therapeutics        HST-104        In pre-clinical

5        HemoShear Therapeutics        methylmalonic acidemia        In pre-clinical

6        LogicBio        LB-001        In pre-clinical

7        Selecta Biosciences        SEL-302        In pre-clinical

Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Stargardt Disease

Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Stargardt disease is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. The disease causes progressive damage — or degeneration — of the macula, which is a small area in the center of the retina that is responsible for sharp, straight-ahead vision. In most cases, Stargardt macular degeneration is caused by mutations in the ABCA4 gene. Less often, mutations in the ELOVL4 gene cause this condition. The ABCA4 and ELOVL4 genes provide instructions for making proteins that are found in light-sensing (photoreceptor) cells in the retina.

Classification-

Fishman STGD Classification

Stage 1:

Pigmentary changes in the macula or pisciform ring of flecks within 1 DD on all sides of the fovea.

           ERG and EOG are normal

      Stage 2:

            Pisciform flecks present beyond 1 DD of the fovea, often extending beyond the arcades and nasal to the optic disc

            ERG and EOG normal, but cone/rod response may be subnormal

     Stage 3:

           Diffusely resorbed flecks and choriocapillaris atrophy of the macula

           EOG subnormal

           ERG subnormal cone or rod amplitudes

          Central field defects + midperipheral/peripheral field defect

    Stage 4:

          Diffusely absorbed flecks and choriocapillaris/RPE  atrophy throughout the entire fundus

          ERG with reduced rod and cone amplitudes

          Peripheral fields with moderate to extensive restriction

Epidemiology- Stargardt macular degeneration is the most common form of juvenile macular degeneration, the signs and symptoms of which begin in childhood. A prospective epidemiologic study (Cornish et. al 2017) undertaken under the auspices of the British Ophthalmological Surveillance Unit (BOSU) suggests an annual incidence in the United Kingdom of between 0.110 and 0.128 per 100 000 individuals. Thelansis estimated prevalence of Stargardt macular degeneration is 1 in 8,000 to 10,000 individuals.

Competitive landscape of Stargardt Disease includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Stargardt Disease across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Stargardt Disease Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Partner        Phase

1        ACU-4429        Kubota Pharmaceutical Holdings Co., Ltd.        N/A        III

2        Zimura        Iveric Bio        Archemix        IIb

3        ALK-001        Alkeus Pharmaceuticals, Inc.        N/A        II

4        ASP7317        Astellas Pharma, Inc.        CHA Bio & Diostech        II

5        LBS-008        Lin Bioscience, Inc.        N/A        I

6        NSR-ABCA4        Biogen, Inc.        N/A        Preclinical

7        QRX-1011        ProQR Therapeutics N.V.        N/A        Preclinical

8        REV-0100        reVision Therapeutics, Inc.        Cornell University        Preclinical

9        Stargardt Program        Applied Genetic Technologies Corporation        N/A        Preclinical

10        STGD1 Minigene Program (IVERIC/UMass)        Iveric Bio        N/A        Preclinical

Neuroendocrine tumors (NETs) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Neuroendocrine tumors (NETs)

Neuroendocrine tumors (NETs) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

A neuroendocrine tumor (NET) is a rare type of tumor that arises from specialized body cells called neuroendocrine cells.

Classification-

There are many types of neuroendocrine tumors, but most are classified as one of two main types:

Carcinoid tumors - NETs that most commonly arise in the digestive tract, lungs, appendix or thymus. They can also grow in the lymph nodes, brain, bone, gonads (ovaries and testes) or skin.

Pancreatic neuroendocrine tumors (also called islet cell tumors) - NETs that typically arise in the pancreas, although they can occur outside the pancreas. A pheochromocytoma is another, rarer type of NET that usually develops in the adrenal gland, but can also arise in other parts of the body

Epidemiology- Thelansis estimates, each year 5.25 out of every 100,000 people in the United States are diagnosed with NET.

Competitive landscape of Neuroendocrine tumors (NETs) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Neuroendocrine tumors (NETs) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Neuroendocrine tumors (NETs) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Neuroendocrine tumors (NETs) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company         Partner        Phase

1        Afinitor        Novartis AG        N/A        Approved (Generic Competition)

2        Sandostatin        Novartis AG        N/A        Approved (Generic Competition)

3        Azedra        Progenics Pharmaceuticals, Inc.        N/A        Approved

4       Demser        Bausch Health Companies Inc.        Ono Pharmaceutical Company        Approved

5        Lutathera        Novartis AG        FUJIFILM        Approved

6        Sandostatin LAR        Novartis AG        N/A        Approved

7        Somatuline Autogel        Ipsen SA        Teijin Pharma        Approved

8        Sutent        Pfizer Inc.        N/A        Approved

9        Unituxin        United Therapeutics Corporation        N/A        Approved

10        Xermelo        TerSera Therapeutics LLC        Ipsen        Approved

11        Danyelza        Y-mAbs Therapeutics Inc.        Memorial Sloan Kettering        BLA

12    EndolucinBeta        ITM Isotopen Technologien München AG        DuChemBio; POINT        III

13   Qarziba        EUSA Pharma Ltd.        Medison; Gen Ilac; Endo International; Apeiron; BeiGene        III

14        ABI-009        AADi Bioscience, LLC        Bristol Myers Squibb        II

15        CPP-1X        Cancer Prevention Pharmaceuticals, Inc.        N/A        II

16        GD2-GD3 Vaccine        Y-mAbs Therapeutics Inc.        MabVax        II

17        Keytruda        Merck & Co., Inc.        DRI Capital        II

18        ONC201        Oncoceutics, Inc.        Ohara Pharmaceutical; NCI        II

19        RRx-001        EpicentRx, Inc.        SciClone Phaarmaceuticals        II

20        Zybrestat (Injectable)        Mateon Therapeutics, Inc        Azanta        II

21        13-CRA        Nova Laboratories Limited        N/A        I/II

22        9-ING-41        Actuate Therapeutics, Inc.        Northwestern        I/II

23        PEN-221        Tarveda Therapeutics, Inc.        N/A        I/II

24        Rozlytrek        Roche Holding AG        SARI; Chugai Pharmaceutical        I/II

25        Sulfatinib        Hutchison China MediTech Limited        N/A        I/II

26        Vorolanib        Xcovery, Inc.        N/A        I/II

27        AlphaMedix        RadioMedix, Inc.        Orano Med        I

28        AUTO6        Autolus Therapeutics plc        N/A        I

29        BOLD-100        Bold Therapeutics, Inc.        Intezyne        I

30        Ceclazepide        Trio Medicines Ltd        N/A        I

31        CLR 131        Cellectar Biosciences, Inc.        N/A        I

32        CMD-501        Kuur Therapeutics        Baylor College of Medicine        I

33        DP1038        Dauntless Pharmaceuticals, Inc.        N/A        I

34        Glide Octreotide        Enesi Pharma Limited        N/A        I

35        Kimozo        Orphelia Pharma SA        Gustave Roussy        I

36        Lorbrena        Pfizer Inc.        N/A        I

37        PV-10        Provectus Biopharmaceuticals, Inc.        Boehringer Ingelheim        I

38        SF1126        SignalRx Pharmaceuticals, Inc        N/A        I

39        SOMTher        Ipsen SA        N/A        I

40        TBR-760        Tiburio Therapeutics, Inc.        Ipsen        I

41        Venclexta        AbbVie Inc.        Roche        I

42        XmAb18087        Xencor, Inc.        N/A        I

43        Cabometyx / Cometriq        Exelixis, Inc.        Swedish Orphan Biovitrum        Investigator Initiated

44        Dacogen        Otsuka Holdings Co., Ltd.        Johnson & Johnson        Investigator Initiated

45        JCAR023        Bristol-Myers Squibb Company        N/A        Investigator Initiated

46        Temodar        Merck & Co., Inc.        N/A        Investigator Initiated

47        CAM2029        Novartis AG        Camurus        Development Outside U.S.

48        F-1614        FUJIFILM Holdings Corp.        N/A        Development Outside U.S.

49        ABTL0812        Ability Pharmaceuticals, SL        Laminar Pharmaceuticals; SciClone Phaarmaceuticals        Preclinical

50        AK-01        Eli Lilly and Company        N/A        Preclinical

51        Kevetrin        Innovation Pharmaceuticals Inc.        MD Anderson Cancer Center        Preclinical

52        OTS167        OncoTherapy Science, Inc.        N/A        Preclinical

53        SNIPER Antibody Program (Invenra/WARF)        Invenra, Inc.        Wisconsin Alumni Research Foundation        Preclinical

54        SVV-001        Seneca Therapeutics, Inc.        N/A        Preclinical

Von Willebrand disease (VWD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Von Willebrand disease (VWD)

Von Willebrand disease (VWD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Von Willebrand disease (VWD) is a blood disorder in which the blood does not clot properly. VWD is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. The VWF gene is located on the short arm (p) of chromosome 12 (12p13). The VWF gene regulates (encodes) VWF. Mutations to this gene result in low levels of VWF, or in VWF that is defective and doesn’t function properly.

Classification-

Type 1- most common and mildest form of VWD, low levels of factor VIII, about 85% of people treated for VWD have Type 1.

Type 2- the body makes normal amounts of the VWF but the factor does not work the way it should, four subtypes― 2A, 2B, 2M, and 2N―depending on the specific problem with the person’s VWF.

Type 3- most severe form of VWD, in which a person has very little or no VWF and low levels of factor VIII. Only 3% of people with VWD have Type 3.

Epidemiology- Thelansis estimates, VWD is the most common bleeding disorder, found in up to 1% of the U.S. population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease. VWD occurs among men and women equally, women are more likely to notice the symptoms because of heavy or abnormal bleeding during their menstrual periods and after childbirth.

Competitive landscape of Von Willebrand disease (VWD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Von Willebrand disease (VWD) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Von Willebrand disease (VWD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Von Willebrand disease (VWD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No     Asset     Company           Phase

1            Factor VIII + von Willebrand factor complex         Octapharma              Launched

2            Factor VIII          Baxter   Launched

3            Alphanate          Grifols  Launched

4            Aleviate              CSL Limited        Launched

5            8Y; Factor VIII/von Willebrand Factor      Bio Products Laboratory              Launched

6            Humate-P           CSL Limited        Launched

7            von Willebrand factor    LFB        Launched

8            vonicog alfa       Baxter   Launched

9            human von Willebrand factor     China Biologic Products Phase I